Business
Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline
MONTPELLIER, France, January 28, 2026--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced a €60 million offering reserved to specific categories of investors (the "Reserved Offering") through the issuance of 214,285,714 new ordinary shares of the Company (the "New Shares") at a price per New Share of €0.28 (the "Subscriptio
About this update from Sanofi Sa
MONTPELLIER, France, January 28, 2026--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced a €60 million offering reserved to specific categories of investors (the "Reserved Offering") through the issuance of 214,285,714 new ordinary shares of the Company (the "New Shares") at a price per New Share of €0.28 (the "Subscription Price") to the benefit of Sanofi for €20 million, and Redmile Group, Artal, which is advised by Invus, and Sofinnova Partners, existing shareholders, and other investors including Cormorant Asset Management, Coastlands Capital and Sphera Healthcare, for €40 million. The settlement-delivery of the Reserved Offering is expected to take place around January 30th, 2026, subject to customary conditions. Sanofi’s investment and participating investors will drive the progression of the genetic medicine pipeline, notably SENS-601 (GJB2-GT). This funding supports key catalysts for the program which targets hearing loss associated with GJB2 mutations, including CTA/IND approval and the enrollment of the first clinical cohort. SENS-601 (GJB2-GT) will be the Company’s second gene therapy program to enter the clinic, following SENS-501, which entered clinical development in 2024. The program targets GJB2 mutations, which are responsible for a significantly larger patient population, accounting for approximately 50% of autosomal recessive non-syndromic congenital hearing loss and implicated in early-onset forms of severe presbycusis in adults. Nawal Ouzren, Chief Executive Officer of Sensorion, said: "We welcome Sanofi’s new strategic investment in Sensorion to advance our pipeline of innovative therapies intended to improve the quality of life of patients suffering from hearing disorders. We are very thankful to the top-tier new investors who joined us and express our gratitude to our existing shareholders who have reaffirmed their support in this transaction. With the additional capital, the Company plans to intensify the ongoing efforts to progress the research and development of SENS-601, including the advancement of the program into its clinical development, and to continue the clinical development of SENS-501 program. T...